Akturk and McKee review emerging type 1 diabetes technologies and therapeutics 

On August 19, Halis Kaan Akturk, MD of the Barbara Davis Center for Diabetes at University of Colorado and Alexis M. McKee, MD of the Division of Endocrinology, Metabolism and Lipid Research at Washington University School of Medicine, had their review titled “Emerging Technologies and Therapeutics for Type 1 Diabetes,” published online by Science Direct. […]

Hogrebe, Ishahak and Millman review stem cell-derived islet replacement therapy for type 1 diabetes 

On May 4, Nathaniel Hogrebe, PhD; Matthew Ishahak, PhD; and Jeffrey Millman, PhD had their review titled “Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes,” published in Cell Stem Cell.  In diabetes treatment, there is great potential for islet-like endocrine clusters from human pluripotent stem cells (hPSCs) to provide a limitless […]

McGill publishes evaluation of the MiniMed 670G HCL in a randomized controlled trial 

On January 1, Janet B. McGill, MD, MA, FACP, and collaborators had their work titled “Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial” published in “Diabetes Technology and Therapeutics.”  The focus was “to evaluate safety and effectiveness of MiniMed™ 670G hybrid closed loop (HCL) in comparison […]

Millman Lab receives funding to improve engraftment of stem cells through genetic engineering 

In January, Jeffrey Millman, PhD was awarded funding of $450,000 from JDRF for his lab’s project titled “Genetic Engineering to Improve Engraftment of Stem Cell-Derived Islets.”    Transplantation of new insulin-producing cells into the patients could be a functional cure for type 1 diabetes. We have developed a method for creating these cells in the lab […]

McKee publishes article on automated insulin delivery 

On November 18, Alexis M. McKee, MD, CDCES had her article titled “What is Automated Insulin Delivery,” published on “EndocrineWeb.”  Automated insulin delivery (AID) delivers insulin through a pump that communicates with a continuous glucose monitor (CGM). Also known as a hybrid closed hoop system or an artificial pancreas device system.  In the article, McKee […]

McGill and sub-investigators’ trial for insulin-only bionic pancreas improves type 1 diabetes management 

On September 28, the National Institutes of Health released information on a pivotal trial for the insulin-only bionic pancreas study. The trial was led by principal investigator, Janet B. McGill, MD, and sub-investigators, Julie M. Silverstein, MD; Maamoun Salam, MD; Samantha Adamson, MD, PhD; and Andrea Cedeno, MD.   The bionic pancreas is unique, closed-loop insulin pump, […]

McGill, Salam and McKee get first patient for clinical trial testing Biosense device for those with Type 1 Diabetes 

Washington University School of Medicine recently received a two-year grant of $360,000 from JDRF to fund research testing the efficacy of the Biosense handheld breath ketone monitor in persons with type 1 diabetes during care with insulin and with the addition of a sodium glucose transporter inhibitor drug.  Biosense is a non-invasive option to capillary […]

McKee publishes article on Neutral Protamine Hagedorn insulin 

On September 12, Alexis McKee, MD published an article on “EndocrineWeb,” titled “What Is the Peak Time for NPH Insulin?”  “Insulin is a lifesaving hormone that is necessary for cells in your body to absorb sugar (glucose). Depending on the type of diabetes mellitus a person has, there can be a complete absence of insulin (type […]